Invivo anti-Human CD20 Recombinant mAb
Invivo anti-Human CD20 Recombinant mAb
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD20 |
| Synonyms | B-lymphocyte antigen CD20; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; MS4A1 |
| Location | Cell membrane |
| Accession | P11836 |
| Clone Number | 2H7 |
| Antibody Type | Mouse mAb |
| Isotype | Mouse IgG2b,k |
| Isotype Control | Invivo mouse IgG2b, κ isotype control |
| Application | FCM, in vivo cell specific depletion |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 5 mg/ml |
| Purity | >95%(Determined by SDS-PAGE) |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Dilution
| application | dilution | species |
| FCM | 1:500 | Hu |
Background
CD20, also known as B-lymphocyte antigen CD20, is a 33–37 kDa non-glycosylated protein primarily expressed on the surface of B cells from the pre-B cell stage through maturity, but it is absent on plasma cells. It is encoded by the MS4A1 gene and belongs to the membrane-spanning 4A gene family. CD20 is a transmembrane protein with four hydrophobic transmembrane domains, one intracellular domain, and two extracellular loops. Although its exact biological function remains unclear, it is believed to play a role in B cell activation and proliferation by facilitating calcium influx. CD20 is an important therapeutic target for B cell malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, as well as for some autoimmune diseases. Anti-CD20 monoclonal antibodies, like Rituximab, work through mechanisms including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and hyper-crosslinking.
